Growth Hormone-Releasing Hormone (1-44) amide

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.

How it works

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that binds to GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone. This leads to increased lipolysis, enhanced fat metabolism, and specific reduction in visceral adipose tissue, particularly effective in treating HIV-associated lipodystrophy. The FDA-approved mechanism targets visceral fat through growth hormone-mediated metabolic pathways.

Viceral Fat Reduction – IGF-1 Enhancement – Body Composition